Caroline Helwick

In the neoadjuvant I-SPY2.2 trial, a treatment strategy including the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), partnered with the PD-L1 inhibitor durvalumab, yielded a high pathologic complete response rate, especially in immune-positive and “all-negative” subtypes. 1

Attendees at the European Society for Medical Oncology (ESMO) Congress 2024 heard the results of many positive clinical trials that will advance the field of cancer treatment. However, a few late-stage trials of promising adjuvant therapies unexpectedly reported negative results. The ASCO Post considers these findings to be just as important to our readers and have summarized some of them here.

In a phase III study conducted in China, the bispecific antibody (targeting both PD-1 and the vascular endothelial growth factor [VEGF]) ivonescimab was compared with the PD-1 inhibitor pembrolizumab as first-line treatment of PD-L1–positive advanced non–small cell lung cancer (NSCLC). Ivonescimab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, according to

In addition to our in-depth analysis of important clinical trials presented at the European Society for Medical Oncology (ESMO) Congress 2024, there is always room for more coverage from The ASCO Post, including these brief summaries of other presentations of interest. They focus on a potential biomarker in bladder cancer treatment, a novel treatment in MTAP-deleted solid tumors, an immunotherapy combination for non–clear cell renal cancer, and first-line combinations with an antibody-drug conjugate in HER2-positive upper gastrointestinal cancers.

The p53-MDM2 inhibitor siremadlin given with the CDK4/6 inhibitor ribociclib showed activity in a subset of patients with well-differentiated/dedifferentiated liposarcomas enrolled in the biology-driven adaptive phase II MEGAMOST Ribociclib/HDM201 basket trial. 1 MEGAMOST was designed to evaluate the clinical benefit of molecularly driven treatment matched to molecular alterations in advanced solid tumors. Mehdi Brahmi, MD, of the Centre Leon Berard and Cancer Research Center of Lyon in France, presented the results of the cohort who received siremadlin and ribociclib.

A recent study found no harm in extending the interval for repeat colonoscopy from 10 to 15 years in certain patients.

In the final per-protocol analysis of the phase III KEYNOTE-811 trial, an overall survival benefit was shown by adding the PD-1 inhibitor pembrolizumab to trastuzumab and chemotherapy in treatment-nai...

The final overall survival analysis of the phase III PRIMA trial found no survival benefit for maintenance niraparib over placebo in advanced ovarian cancer. However, the PARP inhibitor continued to exert a sustained progression-free survival benefit, investigators reported at the European Society for Medical Oncology (ESMO) Congress 2024. 1

In the phase III IMROZ trial, the addition of the anti-CD-38 monoclonal antibody isatuximab-irfc to bortezomib, lenalidomide, and dexamethasone (VRd) was more effective than VRd alone as initial therapy in patients ≤ 80 years with newly diagnosed multiple myeloma ineligible for transplant, investigators reported at the 2024 International Myeloma Society Annual Meeting. 1

PHILADELPHIA—The risks for repeat colonoscopy and post-colonoscopy bleeding were found to be higher among patients whose index colonoscopy was performed by endoscopists who frequently perform hot snare polypectomy, a retrospective analysis of more than 1.5 million colonoscopies has found.